Safety & side effects
Liraglutide has been in US use since its 2010 approval, so its side effects are unusually well mapped.
A well-characterized profile, with real warnings
Liraglutide has been in US use since its 2010 approval, so its side effects are unusually well mapped. Most are gastrointestinal and fade with titration, but both labels also carry a boxed warning for thyroid C-cell tumors and warnings covering pancreatitis, gallbladder disease, kidney injury, severe gastrointestinal reactions and pulmonary aspiration under anesthesia. The two labels are not identical, and this unit names which one each fact comes from.
This unit separates the common-but-manageable from the rare-but-serious, walks the contraindications and interactions, and closes with an honest ceiling. The goal is a calibrated view: neither alarmist about a well-studied drug nor dismissive of genuine, labeled risks.